Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
The "Acute Myeloid Leukemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global ...
Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...
Panelists discuss how implementing oral regimens faces significant operational barriers including formulary restrictions, prior authorization requirements, insurance coverage differences between ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Given the biological complexity of acute ...
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. The National Cancer Institute estimates 20,800 new cases of AML will be diagnosed ...
Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...
Ligufalimab targets CD47, enhancing macrophage-mediated cancer cell destruction, and avoids red blood cell clumping, improving safety and efficacy. Early trials show ligufalimab, combined with Vidaza ...
NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The acute myeloid leukemia (AML) treatment market in APAC size is estimated to grow by USD 305.8 million from ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback